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In their review article, Patel et al1 elegantly described the pro-
cess of ageing of the small bowel under normal conditions. In order
to properly introduce the topic, it is reasonable to add information
about the aging stomach and colon, as evidence shows age-related
declines in these structures.
Along with hypochlorhydria (that can predispose the elderly to
small intestine overgrowth, Fe malabsorption, and vitamin B12
deﬁciency), evidence suggests that reduction in gastric compliance,
particularly of the fundus, plays an important role in the anorexia of
ageing and satiety response.2 The loss of neurons in both submuco-
sal, gastric and enteric plexus begins early in life, along with a
reduction in the expression of acetylcholine (ACh) and nitric oxide
(NO).1,2 Furthermore, orexigenic factors like neuropeptide Y decline
with ageing, and leptin (a hormone related to satiety) have been
shown to increase, particularly in men, probably due to a decrease
in testosterone.2
The increase in colonic transit time and decline in propulsive ac-
tivity are hypothesized to be related to neurodegeneration and
reduction in NO and ACh, making the elderly prone to constipa-
tion.2 The colon plays little role in nutrition, but is an important
element for gut microbiome; the number of colony-forming units
(CFU) increases from 102 CFU in the upper small bowel to 1012
CFU in the colon.2
As the authors stated,1 the gut microbiota plays an important
role in the maintenance of the host health and disease in all age
groups, but particularly in the elderly.3 The mechanisms related
to the beneﬁts of probiotics are incompletely understood.
However, four general beneﬁts have been described: (1) suppres-
sion of growth or epithelial binding/invasion by pathogenic bac-
teria, (2) improvement of intestinal barrier function,
(3) modulation of the immune system, and (4) modulation of
pain perception.1,3,4
The majority of bacteria in the colon are anaerobes that can
ferment carbohydrates that escape digestion, to form short chain
fatty acids (SCFAs) and anions that have a distinct role in promot-
ing gut health (e.g., acetate, propionate, and butyrate).3 Studies
in the elderly described a shift in the composition of intestinal
microbiota, with a lower number of beneﬁcial organisms such
as biﬁdobacteria and lactobacilli1 and an increase in Enterobac-
teriaceae and certain Proteobacteria.3 Compared to younger
adult controls, aged persons seem to have a lower number of Fir-
micutes and more abundant Bacteroidetes.3 Butyrate is the majorhttp://dx.doi.org/10.1016/j.jcgg.2014.01.001
2210-8335/Copyright  2014, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Penergy source for the colonic epithelium, and its levels are usu-
ally lower in the elderly, with concomitant increased levels of
SCFAs, ammonia, and phenols.3 Evidence showed that lactate
accumulation in the colon might be indicative of gut microbiome
imbalance, and it was suggested that this could be a target for
the development of novel probiotics to prevent lactate
accumulation.3
Despite previous good to moderate evidence of the beneﬁcial
effects of probiotic and synbiotic administration, recent larger
randomized controlled trials reported contradictory results
related to the reduction in the risk of infections [Clostridium difﬁ-
cile-associated diarrhea (CDAD), upper respiratory tract infec-
tions, antibiotic-associated-diarrhea (AAD), etc.]. The PLACIDE
Trial reported no evidence of a multi strain preparation of lacto-
bacilli and biﬁdobacteria in the prevention of AAD and CDAD.4
Another recent large trial evaluated the evidence of the preven-
tive effect of probiotics on upper respiratory tract infections
(URTI) in an aged sample, and was unable to ﬁnd differences be-
tween groups.5 Only in the subgroup analysis did the authors
ﬁnd that probiotics probably reduced the duration of acute
URTI.5
Despite good evidence of the clinical beneﬁt of probiotic use in
children and under some speciﬁc conditions, there are no meta-
analysis and systematic reviews, to date, that address the use of
probiotics in the elderly for infection prevention and control. This
issue, we hope, will soon be covered by a systematic review proto-
col that we are already developing.
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